The Effects of Glucose Control and Weight Loss Between Beinaglutide and Dulaglutide in Type 2 Diabetes With Overweight or Obesity.
A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 120 participants.
Also called NCT05005741
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 120 participants
- Sponsor
- Registry
-
NCT05005741
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Unknown status
Technical summary
Registry record NCT05005741. Randomized; no masking; primary purpose treatment. Start 2021-05-01 (actual); primary completion 2023-12-31 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- The Effects of Glucose Control and Weight Loss Between Beinaglutide and Dulaglutide in Type 2 Diabetes With Overweight or Obesity.
- Condition
- Diabetes Mellitus, Type 2
- Condition
- Overweight or Obesity
- Intervention (Drug)
- Beinaglutide
- Intervention (Drug)
- Dulaglutide
- Lead sponsor
- Second Xiangya Hospital of Central South University
- Collaborator
- Guangdong Provincial People's Hospital
- Collaborator
- First Affiliated Hospital of Harbin Medical University
- Collaborator
- The First Affiliated Hospital of Henan University of Science and Technology
Record details
- Record id
cardio:ct-nct05005741- Content hash
6527cced9ba6f2a125e5f01637f283fdb3fb0c65a708a7c6c672fed1cd2ff56b